## PATENT COOPERATION TREAT Y

	From the INTERNATIONAL BUREAU
PCT	То:
NOTIFICATION OF ELECTION	United States Patent and Trademark
(PCT Rule 61.2)	Office (Box PCT)
,, , , , , , , , , , , , , , , , , , , ,	Crystal Plaza 2
	Washington, DC 20231 ÉTATS-UNIS D'AMÉRIQUE
Date of mailing (day/month/year)	1
23 April 1999 (23.04.99)	in its capacity as elected Office
International application No.	Applicant's or agent's file reference
PCT/US98/15148	07265/133WO1
International filing date (day/month/year)	Priority date (day/month/year)
24 July 1998 (24.07.98)	31 July 1997 (31.07.97)
Applicant	
LEE, Se-Jin et al	
CCL, Se-om et al	
The designated Office is hereby notified of its election made	e:
X in the demand filed with the International Preliminar	y Examining Authority on:
24 February 1	999 (24.02.99)
in a notice effecting later election filed with the inter	national Bureau on:
	<del></del>
2. The election X was was not	
made before the expiration of 19 months from the priority Rule 32.2(b).	date or, where Rule 32 applies, within the time limit under
The International Bureau of WIPO	Authorized officer
34, chemin des Colombettes 1211 Geneva 20, Switzerland	Lazar Joseph Panakal
Faccimile No : (41-22) 740 14 36	Telephone No : (41, 22), 239, 93, 38

# **PCT**

PCT V: PO

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 07265/133W01	FOR FURTHER ACTION	TION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)		
International application No.	International filing date (da	y/month/year)	Priority date (day/month/year)	
PCT/US98/15148	24 JULY 1998		31 JULY 1997	
International Patent Classification (IPC) Please See Supplemental Sheet.	or national classification and	IPC		
Applicant THE JOHNS HOPKINS UNIVERSITY	SCHOOL OF MEDICINE			
Examining Authority and is	transmitted to the applican	as been prepa	red by this International Preliminary Article 36.	
2. This REPORT consists of a				
been amended and are the (see Rule 70.16 and Section 1)	e basis for this report and/or tion 607 of the Administrati	sheets containir	cription, claims and/or drawings which have no rectifications made before this Authority, ander the PCT).	
These annexes consist of a to	otal of <u> </u>			
3. This report contains indication	ns relating to the following	items:		
I X Basis of the repo	rt			
II Priority				
			in the principle and indicate in	
		novelty, inven	tive step or industrial applicability	
IV Lack of unity of				
V X Reasoned statemer citations and expla	V X Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
VI Certain documents	VI Certain documents cited			
VII Certain defects in the international application				
VIII X Certain observation				
	A Standard Control of the Contro			
Date of submission of the demand	Da	te of completion	of this report	
24 FEBRUARY 1999		04 NOVEMBE	R 1999	
Name and mailing address of the IPEA/		thorized officer	( ) P	
Commissioner of Patents and Tradem Box PCT Washington, D.C. 20231	arks	PREMA MER	rz D'Z	
Facsimile No. (703) 305-3230	Te	ephone No. (	703) 308-0196	

International application No.

PCT/US98/15148

I.	Basis of t	he report		
1.	This report ha under Article	s been drawn on the 14 are referred to in	basis of (Substitute sheet this report as "originally f	ts which have been furnished to the receiving Office in response to an invitation shall are not annexed to the report since they do not contain amendments):
	x		l application as orig	
	×	the description,	pages 1-27	, as originally filed.
			pages NONE	, filed with the demand.
			pages NONE	, filed with the letter of
			pages	, filed with the letter of
	X	the claims.	Nos <u>1-42</u>	, as originally filed.
				, as amended under Article 19.
			Nos NONE	, filed with the demand.
			Nos NONE	, filed with the letter of
			Nos.	, filed with the letter of
	x	the drawings.	sheets <del>/lig</del> 1	, as originally filed.
	اث		heets#ig NONE	, filed with the demand.
			sheets/fig NONE	, filed with the letter of
			:heets/ <del>fig</del>	, filed with the letter of
2	x x	the description	noted in the cancellation  pages NONE  Nos NONE  sheets/fig NONE	·
3	. Thi	s report has been ego beyond the discl	established as if (some osure as filed, as indica	of) the amendments had not been made, since they have been considered ated in the Supplemental Box Additional observations below (Rule 70.2(c)).
	1. Additions	al observations, i	f necessary:	

International application No. PCT/US98/15148

III. No	n-establishment of opinion with regard to novelty, inventive step and industrial applicability
The ques	stion whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be illy applicable have not been and will not be examined in respect of
	the entire international application.
X	claims Nos. <u>12-42</u>
because	
	the said international application, or the said claim Nos. relate to the following subject matter which does not require international preliminary examination (specify).
	•
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify).
	the claims, or said claims Nos _ are so inadequately supported by the description that no meaningful opinion could be formed.
x	no international search report has been established for said claims Nos. 12-42.

International application No.

PCT/US98/15148

STATEMENT			
Novelty (N)	Claims Claims	1-11 NONE	
Inventive Step (IS)	Claims Claims		
Industrial Applicability (IA)	Claims Claims	I-II NONE	YES NO
laims 1-11 meet the criteria set out in PCT ifferentiation factor-16 (GDF-16), a polynuc	Article 33(2)-( eleotide encodii		n or fairly suggest growth
1	Industrial Applicability (IA)  CITATIONS AND EXPLANATION laims 1-11 meet the criteria set out in PCT ifferentiation factor-16 (GDF-16), a polynuc	Claims  Industrial Applicability (IA)  Claims  Claims  CITATIONS AND EXPLANATIONS  laims 1-11 meet the criteria set out in PCT Article 33(2)-(  Ifferentiation factor-16 (GDF-16), a polynucleotide encoding  NEW CITATIONS	Claims NONE  Industrial Applicability (IA)  Claims 1-11  Claims NONE  CITATIONS AND EXPLANATIONS  laims 1-11 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach (Ifferentiation factor-16 (GDF-16), a polynucleotide encoding GDF-16, a vector and a host cell.  NEW CITATIONS

International application No. PCT/US98/15148

#### VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The description is objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 5 because it fails to adequately enable practice of the claimed invention because:

the description is not enabling for "all GDF-16" as recited in claim 1, because the description only enables a GDF-16 of amino acid sequence shown in Figure 1, the polypeptide having specific characteristics. The term "GDF-16" encompasses amino acid sequences that can deviate from the amino acid sequence shown in Figure 1, therefore, different proteins with different amino acid sequences but the activity of GDF-16 would be encompassed by the claims. Specifically, the instant description does not identify those amino acid residues in the amino acid sequence of GDF-16 which are essential for its biological activity and structural integrity and those residues which are either expendable or substitutable. In the absence of this information a practitioner would have to resort to a substantial amount of undue experimentation in the form of insertional, deletional and substitutional mutation analysis of over 100 amino acid residues before they could even begin to rationally design a functional GDF-16 polypeptide having other than a natural amino acid sequence. The disclosure of a single natural amino acid sequence is clearly insufficient support for claims which encompass any and all GDF-16 polypeptides, including mutants thereof.

Claims 1-2, 4-11 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because practice of the claimed invention is not enabled as required under PCT Rule 5.1(a) for the reasons set forth in the immediately preceding paragraph.

Claim 3 is objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because the claim is indefinite for the following reason:

Claim 3 recites "hybridize", which is a conditional limitation because a polynucleotide which could hybridize under conditions of low stringency to DNA encoding the GDF-16 polypeptide of Figure 1, might fail to hybridize under conditions of high stringency.



International application No.

PCT/US98/15148

ontinuation of: Boxes I - VIII	Sheet 10
ontinuation of Boxes 1 - viii	Sheet 10
**LASSIFICATION: The International Patent Classification (IPC) and/or the National classific C(6): C12N 15/12, 15/16, 15/18, 15/63, 15/64, 15/66; C07K 14/46, 14/47, 1.2, 325, 471, 252.3, 320.1	fication are as listed below: 14/475 and US Cl.: 530/350; 435/69.1, 7
	_
	•



#### WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) WO 99/06556 (51) International Patent Classification 6: (11) International Publication Number: C12N 15/12, 15/16, 15/18, 15/63, 15/64, 15/66, C07K 14/46, 14/47, 14/475 **A1** 11 February 1999 (11.02.99) (43) International Publication Date: (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, PCT/US98/15148 (21) International Application Number: BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, (22) International Filing Date: 24 July 1998 (24.07.98) LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO (30) Priority Data: patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian 31 July 1997 (31.07.97) US 60/054,606 patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, (63) Related by Continuation (CON) or Continuation-in-Part CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). (CIP) to Earlier Application 60/054,606 (CON) US 31 July 1997 (31.07.97) Filed on Published With international search report. (71) Applicant (for all designated States except US): THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE [US/US]; 720 Rutland Avenue, Baltimore, MD 21205 (US). (72) Inventors: and (75) Inventors/Applicants (for US only): LEE, Se-Jin [US/US]; 6711 Chokeberry Road, Baltimore, MD 21209 (US). HUYNH, Thanh, V. [US/US]; 5510 South Bend Road, Baltimore, MD 21209 (US). SEBALD, Suzanne [US/US]; 1836 Montevideo Road, Jessup, MD 20794 (US). (74) Agent: HAILE, Lisa, A.; Fish & Richardson P.C., Suite 1400, 4225 Executive Square, La Jolla, CA 92037 (US). (54) Title: GROWTH DIFFERENTIATION FACTOR-16 (57) Abstract Growth differentiation factor-16 (GDF-16) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diganostic and therapeutic methods of using the GDF-16 polypeptide and polynucleotide sequences.

#### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	rc	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## INTERNATIONAL SEARCH REPORT

international application No.

PCT/L	JS98/1	15148
-------	--------	-------

	SSIFICATION OF SUBJECT MATTER		
US CL :	Please See Extra Sheet. 530/350; 435/69.1, 71.1, 71.2, 325, 471, 252.3, 320.1	l	
	o International Patent Classification (IPC) or to both	national classification and IPC	
	DS SEARCHED ocumentation scarched (classification system follower	d by classification symbols)	
	530/350; 435/69.1, 71.1, 71.2, 325, 471, 252.3, 320.1		
Documentati NONE	ion searched other than minimum documentation to the	extent that such documents are included	in the fields searched
	ata base consulted during the international search (nace Extra Sheet.	ame of data base and, where practicable,	search terms used)
C. DOC	UMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.
A	WO 94/15949 A1 (JOHNS HOPKINS MEDICINE) 21 July 1994 (21/07/94).		1-11
A	WO 86/06076 A1 (BIOTECHNOLOG 23 October 1986 (23/10/86), see entir		1-11
Furth	ner documents are listed in the continuation of Box C	C. See patent family annex.	
	ecial categories of cited documents:	"T" later document published after the integrated and not in conflict with the app	emetional filing date or priority
'A' do	cusment defining the general state of the art which is not considered be of perticular relevance	the principle or theory underlying the	s unvention
.в. •=	riser document published on or after the international filing data	"X" document of particular relevance; the considered novel or cannot be conside when the document is taken alone	e claimed invention cannot be red to involve an inventive step
cata	eument which may throw doubts on priority claus(s) or which is ad to establish the publication date of another citation or other social reason (as specified)	"Y" decument of particular relevance: th	e claimed invention cannot be
•0• do	comment referring to an oral disclosure, use, exhibition or other	considered to savolve an inventive combined with one or more other such being obvious to a person skilled in t	h documents, such combination the art
*P* do	cument published prior to the international filing date but later than a priority date cleaned	'&' document member of the same patent	
	actual completion of the international search	Date of mailing of the international sea	arch report
	BER 1998		9
Box PCT	mailing address of the ISA/US mer of Patents and Trademarks n. D.C. 20231	PREMA MERKELLE	Clens for
Facsimile N		Telephone No. (709) 308-0196	<del>()</del>
Form PCT/I:	SA/210 (second sheet)(July 1992)#		V

#### INTERNATIONAL SEARCH REPORT

International application No. PCT/US98/15148

Во	ı I O	bservations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
Thi	inten	national report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.		Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2.		Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.		Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Bo	t II (	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
Ты	s inte	mational Searching Authority found multiple inventions in this international application, as follows:
	Pie	ease See Extra Sheet.
1.		As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.		As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.		As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.	[X] 1.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Rei	nsrk	on Protest The additional search fees were accompanied by the applicant's protest.
		No protest accompanied the payment of additional search fees.

#### INTERNATIONAL SEARCH REPORT

International application No. PCT/US98/15148

A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

C12N 15/12, 15/16, 15/18, 15/63, 15/64, 15/66; C07K 14/46, 14/47, 14/475

#### B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAS ONLINE, MEDLINE, BIOSIS, EMBASE, CAPLUS search terms: growth differentiation factor-16, GDF-16, DNA, polynucleotide, nucleic acid, polypeptide, protein, recombinant, cloning.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-11, drawn to growth differentiation factor-16 (GDF-16), a polynucleotide encoding GDF-16, a vector and a host cell

Group II, claims 12-14, drawn to antibodies that bind GDF-16.

Group III, claims 15-21, drawn to a method of detecting a cell proliferative disorder in a specimen using antibodies that bind GDF-16.

Group IV, claims 22-23, 25-41, drawn to a method of treating a cell proliferative disorder with antibodies that bind GDF-16

Group V, claims 22, 24-38, drawn to a method of treating a cell proliferative disorder with a GDF-16 antisense source.

Group VI, claim 42, drawn to a method for identifying a GDF-16 receptor polypeptideusing a cell expressing a GDF-16 receptor or a soluble receptor.

The inventions listed as Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions listed as Groups I-VI do not relate to a single

inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical

features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the

main invention (Group I) comprises the first-recited product, GDF-16, a polynucleotide encoding GDF-16, a vector and a host cell. Further pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.